Organization

Delfi Diagnostics, Inc.

6 abstracts

Abstract
Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.
Org: Delfi Diagnostics, Inc., National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Institute, Vilnius, Lithuania, DELFI Diagnostics, The Johns Hopkins University School of Medicine,
Abstract
Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.
Org: Delfi Diagnostics, Inc., DELFI Diagnostics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Cell-free DNA fragmentation profiling for therapeutic response monitoring in metastatic colorectal cancer.
Org: Delfi Diagnostics, Inc., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Netherlands Cancer Institute (Netherlands), The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL, The Johns Hopkins University School of Medicine,
Abstract
Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.
Org: NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, University of Pennsylvania, Delfi Diagnostics, Inc., The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL,
Abstract
Failure rates of mutation-based ctDNA assays in lung cancer treatment monitoring.
Org: Johns Hopkins University Bloomberg School of Public Health, DELFI Diagnostics, Delfi Diagnostics, Inc., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine,